Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing ...

Trump is “in peak physical and mental condition,” White House Press Secretary Karoline Leavitt told The Atlantic in an ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.